Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14588871 | 1.00 | KMT2A (0.39) | KMT2ANCF1OPRM1MAPK1SMN1; SMN2 | |
| SCHEMBL12457716 | 0.80 | — | — | |
| SCHEMBL14431948 | 0.74 | KMT2A (0.40) | KMT2ANCF1MAPK1SMN1; SMN2 | |
| SCHEMBL18968291 | 0.73 | — | — | |
| SCHEMBL10306161 | 0.73 | — | — | |
| SCHEMBL14139659 | 0.73 | — | — | |
| SCHEMBL90594 | 0.73 | — | — | |
| SCHEMBL17972988 | 0.73 | KMT2A (0.47) | KMT2ANCF1OPRM1MAPK1SMN1; SMN2 | |
| SCHEMBL18968813 | 0.73 | — | — | |
| SCHEMBL731296 | 0.72 | GRIN2D (0.32) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-2686320-B1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-09-03 | — | — | US | disclosed |
| US-8946422-B2 | 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2014043272-A1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | TRIUS THERAPEUTICS INC. (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2012125746-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2130827-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090012071-A1 | 4-SUBSTITUTED-1H-ISOTHIAZOLO[5,4-B][1,4]OXAZINO[2,3,4-IJ]QUINOLINE-7,8(2H,9H)-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1930006-A1 | METHOD FOR PRODUCTION OF QUINOLONE-CONTAINING LYOPHILIZED PREPARATION | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | NQO2, TREH, CYP51A1 | KMT2A 3603/4885NCF1 1645/4885OPRM1 4250/4885 |
| US-20090012071-A1 | 4-SUBSTITUTED-1H-ISOTHIAZOLO[5,4-B][1,4]OXAZINO[2,3,4-IJ]QUINOLINE-7,8(2H,9H)-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | TOP1, TOP2B, TOP2A | KMT2A 2301/4885NCF1 1653/4885OPRM1 3701/4885 |
| US-20150246934-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | KMT2A 3484/4885NCF1 1740/4885OPRM1 3994/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | KMT2A 3095/4885NCF1 1880/4885OPRM1 4072/4885 |
| US-20170369498-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | KMT2A 3095/4885NCF1 1880/4885OPRM1 4072/4885 |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | NQO2, QPCT, QARS1 | KMT2A 1992/4885NCF1 849/4885OPRM1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.